aTyr Pharma, Inc. (LIFE)
(Delayed Data from NSDQ)
$0.62 USD
+0.01 (1.61%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.62 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
aTyr Pharma, Inc. [LIFE]
Reports for Purchase
Showing records 1 - 20 ( 175 total )
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Smooth Sailing Ahead as Phase 3 EFZO-FIT Receives Second Positive DSMB Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Continued Execution for Efzofitimod; Enrollment Completion for Phase 3 EFZO-FIT Study Expected 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Efzofitimod Marches Forward; EFZO-FIT Enrollment Aims to Finish in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Furthering Efzo''s Reach With Expanded Access Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Efzo Displays Promise in Rheumatoid Arthritis, Expanding the Drug''s Therapeutic Versatility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; All Focus On Progress Efzo Through Clinic; Phase 3 EFZO-FIT Enrollement Completion Expected 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Efzo Starts to CONNECT In SSc-ILD; First Patient Dosed in Phase 2 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Efzo Initiates Its Systemic-Sclerosis Journey in the Phase 2 EFZO-CONNECT Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Untapped Opportunities: A Potential Path to Expand Efzofitimod''s Clinical Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Efzo Efficacy Profile Continues to Build With Positive Phase 1b/2a Post-Hoc Analysis Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Efzo Expands in the Clinic; Phase 2 EFZO-CONNECT in SSc-ILD to Initiate 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Programs Advancing, Funded Through Inflection Points
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ATS Further Strengthens Efzo''s Profile as Next- Gen Immunomodulator for Pulmonary Sarcoidosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Efzofitimod Clinical Development Forges Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Efzofitimod Pulmonary Sarcoidosis Phase 3 Advancing, SSc-ILD Phase 2 in Q3
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ATYR2810 Exhibits Early Promise in Aggressive Cancers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J